There is a need to improve personalized immunosuppression in organ transplantation to
reduce premature graft loss. Biomarkers are needed to better detect rejection, asymptomatic …

Nirmatrelvir/ritonavir (Paxlovid) consists of a peptidomimetic inhibitor (nirmatrelvir) of the
SARS-CoV-2 main protease and a pharmacokinetic enhancer (ritonavir). It is approved for …

Aims Immunosuppressant and kidney function monitoring are crucial for kidney transplant
recipient follow‐up. Microsamples enable remote sampling and minimise patient burden as …

Therapeutic drug monitoring of mycophenolic acid (MPA) based on area under the curve
(AUC) is well‐established and machine learning (ML) approaches could help to estimate …

Therapeutic drug monitoring (TDM) of immunosuppressants is essential to avoid either
rejection or toxicity after solid organ transplantations. Capillary microsampling approaches …

Evidence to define target ranges for tacrolimus (Tac) and mycophenolic acid (MPA)
exposure after the first year of kidney transplantation is limited. We investigated the …

The most frequently used immunosuppressive treatment in kidney transplant recipients is
the combination therapy of a calcineurin inhibitor and mycophenolate mofetil (MMF), with or …

Miniaturisation and simplification are novel approaches in clinical bioanalysis, especially in
therapeutic drug monitoring (TDM). These contemporary trends are related to the sampling …

Immunosuppressive drugs have been key to the success of liver transplantation and are
essential components of the treatment of inflammatory bowel disease (IBD) and autoimmune …

Background: The long-term outcomes of solid organ transplantation remain suboptimal.
Therefore, appropriate biomarkers are needed in addition to immunosuppressive drugs and …